You are here

SARC021

Active
A randomized phase 3, multicenter, open-label study comparing TH-302 in combination with doxorubicin vs. doxorubicin alone in subjects with locally advanced unresectable or metastatic soft tissue sarcoma
Type of Sarcoma: 
locally advanced or metastatic soft tissue sarcoma
Drug: 
TH-302 combined with doxorubicin vs. doxorubicin alone
Accrual Status: 
Open, Not Accruing
Overall Study Principal Investigator: 
William Tap, MD
Memorial Sloan-Kettering Cancer Center

For more information about this trial and open sites: